By F.D. Flam / Bloomberg Opinion
Mainstream medical opinion holds that screening mammography is a lifesaving procedure. But doctors disagree over how often women should be screened for breast cancer. Last week, a panel of doctors known as the U.S. Preventive Service Task Force revived the debate over mammography by issuing a new recommendation. Their old guidelines advised starting at age 50 and getting screened every other year; the new ones keep the every-other-year recommendation but lower the starting age to 40.
Despite the new recommendations, many doctors will maintain that an annual mammogram is a necessity for me and every other woman over 40. But a growing faction warn screening healthy women this frequently might do more harm than good.
I haven’t chosen to get mammograms more than every other year; despite some protests from my doctors. The ideal schedule has to take into account the latest data on risks and benefits. Recent studies show every-other-year screenings still catch tumors early enough for treatment. And annual screenings have been linked to false positives and unnecessary follow-up care, including biopsies and even surgery.
The arguments represent part of a bigger debate in medicine that pits tradition against updated evidence, and calls into question the ethics of heavily marketing or requiring tests or interventions that may not make a meaningful difference; and that, in some cases, may even have a small potential for harm. Screening proponents tend to favor hammering away at the simple message that the procedure “saves lives,” while skeptics advocate for more transparency about limitations and risks, and more freedom for patients to make their own informed decisions.
Some experts argue that we could benefit from more randomized controlled trials; and that the existing trials need to be analyzed more critically. (None of this applies to people who have special risk factors such as the BRCA1 gene, and there’s no question mammography is an important diagnostic tool used when someone has found a lump.)
Rita Redberg, editor in chief of JAMA Internal Medicine and a professor of medicine at UC San Francisco, told me people tend to overestimate the benefits of screening and overlook the harms. Some trials do show a modest reduction in the number of deaths attributed to breast cancer, but not a reduction in deaths overall. That may happen because the overall effect is too small. Breast cancer causes just 2.5 percent of deaths, and reducing that by 10 percent or even 20 percent might make too small a dent in overall deaths to show up in the studies.
I asked her if screening improves quality of life because catching cancer early could help patients dodge debilitating chemotherapy or radical surgery. She said there’s no evidence for that. If anything, more screening leads to more surgery.
Skepticism of screening mammography intensified a few years ago after some surprising studies showed that among women who get screened every year, most will get at least one false positive, and that many small cancers caught by mammography would never have metastasized or caused any health problem if ignored.
The concept of non-threatening cancer is counterintuitive. To help, some researchers use an animal analogy. Some tumors are turtles, and aren’t going anywhere. Some highly malignant ones are birds, and they are getting out no matter what. Screening is only useful for those in the middle; rabbits. Tumors don’t come labeled, however, so doctors may order surgery for the turtles just in case.
In a video created in response to the task force’s new guidelines, UC San Francisco medical professor Vinay Prasad pointed out that a 25-year randomized controlled trial, out of Canada, showed that for healthy, average-risk women, screening mammography did not save lives.
While Prasad dismissed the concern that mammography exposes women to small doses of carcinogenic radiation, Redberg isn’t ready to write that off. Some studies have estimated a small fraction of women who get regularly screened will get cancer from the radiation. Whether that’s an acceptable risk depends on the size of the benefits.
Task force member John Wong, a professor of medicine at Tufts, explained to me that the change in the panel’s recommendations is based on a model, and over the past few years, a number of inputs have shifted. Those included a higher number of detected cancers among women in their 40s, better screening technology, better treatments and persistent health disparities; Black women are more likely to get breast cancer and die from the disease, for reasons that scientists have yet to pinpoint. He thinks the benefits of screening mammography are so clear, it’s unethical to do more randomized trials.
But he also admits that we don’t know why more women in their 40s are getting diagnosed with cancer. Are deadlier cancers striking this group? Or are more turtles being discovered because, no matter what the official guidelines are, many doctors push women in their 40s to get screened? It’s also unclear whether more screening will do anything to improve racial disparities.
Wong asked me if he had convinced me. I am convinced that there’s a need to balance harms and benefits, and I had already used the panel’s earlier recommendation — every other year starting at 50 — to guide my own schedule. But I disagree that it’s unethical to conduct more clinical trials. If he wants to start one, he can sign me up.
F.D. Flam is a Bloomberg Opinion columnist covering science. She is host of the “Follow the Science” podcast.
Talk to us
- You can tell us about news and ask us about our journalism by emailing email@example.com or by calling 425-339-3428.
- If you have an opinion you wish to share for publication, send a letter to the editor to firstname.lastname@example.org or by regular mail to The Daily Herald, Letters, P.O. Box 930, Everett, WA 98206.
- More contact information is here.